Cannabis affects the same liver enzymes that metabolize roughly half of all pharmaceutical drugs. If you use cannabis and take any prescription medication, this is information your prescriber needs to know.
The CYP450 Enzyme System and Cannabis
The cytochrome P450 enzyme family handles the metabolism of approximately 60–70% of pharmaceuticals in the liver and gut. Several CYP enzymes — particularly CYP3A4, CYP2C9, and CYP2C19 — are significantly affected by cannabinoids, especially at the doses used medicinally or recreationally.
CBD is among the more potent inhibitors of CYP2C19 and CYP3A4 studied in clinical contexts. When these enzymes are inhibited, drugs that depend on them for metabolism accumulate at higher blood levels than expected. This is called a pharmacokinetic interaction and can cause both therapeutic and adverse effects of the co-administered drug to intensify.
THC is a moderate inhibitor of CYP3A4 and CYP2C9. Its effects are less potent than CBD’s at typical doses but still clinically relevant for medications with narrow therapeutic windows.
High-Risk Drug Categories
Blood Thinners (Warfarin)
Warfarin is one of the most documented cannabis interactions. CBD and THC both inhibit CYP2C9, the primary enzyme that metabolizes warfarin. Multiple case reports document significantly elevated INR (International Normalized Ratio) values in patients who added cannabis to stable warfarin regimens, increasing bleeding risk. The FDA has issued communication noting this interaction. Anyone taking warfarin should not add cannabis without close INR monitoring and physician guidance.
Epilepsy Medications
The FDA-approved CBD medication Epidiolex carries a label warning about interactions with clobazam (a benzodiazepine anticonvulsant). CBD increases clobazam blood levels significantly, requiring dose adjustments in clinical trials. Similar effects are likely with other antiepileptics metabolized by CYP enzymes. This is particularly relevant because cannabis is often discussed as a complementary approach to epilepsy management.
Immunosuppressants (Tacrolimus, Cyclosporine)
These narrow-therapeutic-index drugs used in organ transplant recipients are primarily metabolized by CYP3A4. Even modest CYP3A4 inhibition can cause significant accumulation, with potentially serious consequences including toxicity or organ rejection. Transplant patients should discuss any cannabis use with their transplant team.
Chemotherapy Agents
Many chemotherapy drugs are CYP substrates. Interactions can work both ways: some drugs may accumulate (increased toxicity), while others that require enzymatic activation may work less effectively (reduced efficacy). Oncologists need to know about cannabis use to manage these interactions.
Opioids
THC and opioids both produce CNS depression. The combination amplifies sedation, respiratory depression risk, and cognitive impairment. Some research suggests cannabinoids may have an opioid-sparing effect in certain pain contexts, but self-adjusting opioid doses based on cannabis use without medical guidance is dangerous. The sedation combination also carries accident and impairment risk.
Benzodiazepines and Sleep Medications
Benzodiazepines (lorazepam, alprazolam, diazepam), z-drugs (zolpidem), and other CNS depressants are significantly potentiated by THC. Combined use amplifies sedation, cognitive impairment, and respiratory depression risk, particularly at higher doses.
Antidepressants and Mood Stabilizers
SSRIs, SNRIs, and tricyclic antidepressants are metabolized by CYP enzymes affected by cannabinoids. Combined use can alter antidepressant blood levels. Additionally, high-THC cannabis can worsen anxiety and mood instability in some individuals, which may complicate depression and bipolar disorder management. Lithium and cannabis co-use has been associated with mania triggering in some case reports.
CBD-Specific Interactions
Because CBD is now widely available as an over-the-counter supplement, many people do not consider it a drug that interacts with their medications. This is a misconception with clinical consequences. CBD at doses used in supplements (typically 25–75mg) can still produce meaningful CYP enzyme inhibition. At the doses used in Epidiolex (typically 5–20mg/kg/day), the interactions are pronounced enough to require active prescriber management.
What to Tell Your Prescriber
Disclosing cannabis and CBD use to healthcare providers is essential for safe prescribing. Key information to share:
- Whether you use THC, CBD, or both
- Approximate dose (mg per day if possible, or frequency of use)
- Route of administration (inhaled, oral, sublingual, topical)
- How long you have been using and at what frequency
In states where cannabis is legal, prescribers should not penalize disclosure. Patients have the right to honest conversations about all substances affecting their health.
This article is for educational purposes only and is not medical advice. Medication interactions require individualized assessment by a licensed healthcare provider. Never change or stop medications based on cannabis interaction concerns without speaking to your prescriber.
Frequently Asked Questions
Does smoking cannabis interact with medications differently than edibles?
The CYP enzyme inhibition from CBD is most relevant with oral consumption, where CBD passes through the liver. Inhaled cannabis produces faster onset with less first-pass liver metabolism, which may reduce but not eliminate CYP interaction potential for THC. CBD oil and edibles are more likely to produce clinically significant enzyme interactions than inhaled cannabis.
Do topical cannabis products interact with medications?
Topical cannabis products have minimal systemic absorption and are unlikely to produce significant CYP enzyme interactions. This makes them lower-risk for drug interaction concerns compared to oral or inhaled cannabis.
